• +1-646-491-9876
    • +91-20-67278686

    Search

    Histone Deacetylase 2-Pipeline Review H2 2017

    Histone Deacetylase 2-Pipeline Review H2 2017

    • Report Code ID: RW00011060483
    • Category Life Sciences
    • No. of Pages 116
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Pipeline Review, H2 2017

    Summary

    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. It interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.

    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) pipeline Target constitutes close to 24 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Lung Cancer, Mantle Cell Lymphoma, Neurodegenerative Diseases, Neurology, Non-Hodgkin Lymphoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Thalassemia, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Asthma, Becker Muscular Dystrophy, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), CNS Lymphoma, Cognitive Disorders, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Gallbladder Cancer, Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, T-Cell Leukemia and Thyroid Cancer.

    The latest report Histone Deacetylase 2-Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
    -The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Global Markets Direct Report Coverage 7
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Overview 8
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Therapeutics Development 9
    Products under Development by Stage of Development 9
    Products under Development by Therapy Area 10
    Products under Development by Indication 11
    Products under Development by Companies 16
    Products under Development by Universities/Institutes 23
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Therapeutics Assessment 25
    Assessment by Mechanism of Action 25
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Companies Involved in Therapeutics Development 31
    4SC AG 31
    Celgene Corp 31
    Chipscreen Biosciences Ltd 32
    Curis Inc 33
    HitGen LTD 34
    Italfarmaco SpA 34
    Medivir AB 35
    MEI Pharma Inc 35
    Merck & Co Inc 36
    Sigma-Tau SpA 37
    Yungjin Pharm Co Ltd 37
    Zhejiang Hisun Pharmaceutical Co Ltd 38
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Drug Profiles 39
    4SC-202-Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    ACY-1035-Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    ACY-1071-Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    ACY-738-Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    ACY-957-Drug Profile 46
    Product Description 46
    Mechanism Of Action 46
    R&D Progress 46
    CS-3158-Drug Profile 49
    Product Description 49
    Mechanism Of Action 49
    R&D Progress 49
    CUDC-907-Drug Profile 50
    Product Description 50
    Mechanism Of Action 50
    R&D Progress 50
    givinostat-Drug Profile 55
    Product Description 55
    Mechanism Of Action 55
    R&D Progress 55
    HG-3001-Drug Profile 58
    Product Description 58
    Mechanism Of Action 58
    R&D Progress 58
    largazole-Drug Profile 59
    Product Description 59
    Mechanism Of Action 59
    R&D Progress 59
    pracinostat-Drug Profile 60
    Product Description 60
    Mechanism Of Action 60
    R&D Progress 60
    RCY-1305-Drug Profile 67
    Product Description 67
    Mechanism Of Action 67
    R&D Progress 67
    RCY-1497-Drug Profile 68
    Product Description 68
    Mechanism Of Action 68
    R&D Progress 68
    RCY-1992-Drug Profile 69
    Product Description 69
    Mechanism Of Action 69
    R&D Progress 69
    remetinostat-Drug Profile 70
    Product Description 70
    Mechanism Of Action 70
    R&D Progress 70
    resminostat-Drug Profile 73
    Product Description 73
    Mechanism Of Action 73
    R&D Progress 73
    Small Molecule to Inhibit HDAC2 for Oncology-Drug Profile 84
    Product Description 84
    Mechanism Of Action 84
    R&D Progress 84
    Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology-Drug Profile 85
    Product Description 85
    Mechanism Of Action 85
    R&D Progress 85
    Small Molecules to Inhibit HDAC2 for Neurological Disorders-Drug Profile 86
    Product Description 86
    Mechanism Of Action 86
    R&D Progress 86
    ST-3595-Drug Profile 87
    Product Description 87
    Mechanism Of Action 87
    R&D Progress 87
    Synthetic Peptide to Inhibit HDAC for Prostate Cancer-Drug Profile 88
    Product Description 88
    Mechanism Of Action 88
    R&D Progress 88
    tucidinostat-Drug Profile 89
    Product Description 89
    Mechanism Of Action 89
    R&D Progress 89
    vorinostat-Drug Profile 93
    Product Description 93
    Mechanism Of Action 93
    R&D Progress 93
    YPL-001-Drug Profile 98
    Product Description 98
    Mechanism Of Action 98
    R&D Progress 98
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Dormant Products 99
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Discontinued Products 102
    Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98)-Product Development Milestones 103
    Featured News & Press Releases 103
    Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 103
    Jul 19, 2017: Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer's Association International Conference 104
    Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 104
    Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 105
    May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 106
    May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 107
    Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 107
    Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 108
    Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 109
    Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup 110
    Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 110
    Jan 11, 2017: Regenacy Pharma's HDAC2 Inhibitor ACY-1035 Demonstrates Potent Anti-Leukemic Activities 111
    Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL 112
    Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 112
    Dec 04, 2016: Acetylon Presents Preclinical Data Demonstrating the Utility of Selective HDAC1,2 Inhibition by ACY-957 to Induce Gamma Globin (HBG) Protein Expression for the Treatment of Sickle Cell Disease and Beta-Thalassemia 113
    Appendix 115
    Methodology 115
    Coverage 115
    Secondary Research 115
    Primary Research 115
    Expert Panel Validation 115
    Contact Us 115
    Disclaimer 116

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 9
    Number of Products under Development by Therapy Areas, H2 2017 10
    Number of Products under Development by Indications, H2 2017 11
    Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
    Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14
    Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15
    Number of Products under Development by Companies, H2 2017 16
    Products under Development by Companies, H2 2017 17
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19
    Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20
    Products under Development by Companies, H2 2017 (Contd..4), H2 2017 21
    Products under Development by Companies, H2 2017 (Contd..5), H2 2017 22
    Number of Products under Investigation by Universities/Institutes, H2 2017 23
    Products under Investigation by Universities/Institutes, H2 2017 24
    Number of Products by Stage and Mechanism of Actions, H2 2017 26
    Number of Products by Stage and Route of Administration, H2 2017 28
    Number of Products by Stage and Molecule Type, H2 2017 30
    Pipeline by 4SC AG, H2 2017 31
    Pipeline by Celgene Corp, H2 2017 32
    Pipeline by Chipscreen Biosciences Ltd, H2 2017 33
    Pipeline by Curis Inc, H2 2017 34
    Pipeline by HitGen LTD, H2 2017 34
    Pipeline by Italfarmaco SpA, H2 2017 35
    Pipeline by Medivir AB, H2 2017 35
    Pipeline by MEI Pharma Inc, H2 2017 36
    Pipeline by Merck & Co Inc, H2 2017 37
    Pipeline by Sigma-Tau SpA, H2 2017 37
    Pipeline by Yungjin Pharm Co Ltd, H2 2017 38
    Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 38
    Dormant Products, H2 2017 99
    Dormant Products, H2 2017 (Contd..1), H2 2017 100
    Dormant Products, H2 2017 (Contd..2), H2 2017 101
    Discontinued Products, H2 2017 102

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 9
    Number of Products under Development by Therapy Areas, H2 2017 10
    Number of Products under Development by Top 10 Indications, H2 2017 11
    Number of Products by Mechanism of Actions, H2 2017 25
    Number of Products by Stage and Mechanism of Actions, H2 2017 25
    Number of Products by Routes of Administration, H2 2017 27
    Number of Products by Stage and Routes of Administration, H2 2017 27
    Number of Products by Molecule Types, H2 2017 29
    Number of Products by Stage and Molecule Types, H2 2017 29
    4SC AG
    Celgene Corp
    Chipscreen Biosciences Ltd
    Curis Inc
    HitGen LTD
    Italfarmaco SpA
    Medivir AB
    MEI Pharma Inc
    Merck & Co Inc
    Sigma-Tau SpA
    Yungjin Pharm Co Ltd
    Zhejiang Hisun Pharmaceutical Co Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//histone-deacetylase-2-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//histone-deacetylase-2-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//histone-deacetylase-2-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments